New Indications, Campaigns, and Trial Results Introduced in the Q4 2025 EU Leukemia and Lymphoma Market 

Bristol Myers Squibb advertised a new Breyanzi indication for the third-line or later treatment of mantle cell lymphoma and reduced post-infusion safety requirements from the European Medicines Agency.

The “From 4 to 2” campaign was introduced as BeOne Medicines emphasized Brukinsa’s new two-tablet-per-day regimen. Meanwhile, the “Easy” theme highlighted the brand’s treatment simplicity.

New lighthouse imagery premiered for Calquence’s “Confidence” theme. AstraZeneca also touted the brand’s approvals for CLL and MCL as well as updated guideline recommendations for each indication.

Johnson and Johnson promoted a new mantle cell lymphoma indication in combination with chemoimmunotherapy alongside the “Time” campaign.

The approval of subcutaneous Lunsumio, financial results, new trial data, and the presentation of data at a conference were announced in Roche press releases.

AbbVie used the “Every Path” campaign to promote Venclyxto’s approval in combination with acalabrutinib, savings, and other benefits.